Form 4: Edwards Lifesciences Executive Reports Routine Share Disposition for Tax Withholding

Edwards Lifesciences CVP, JAPAC Daniel J. Lippis, reported the disposition of 333 common shares at $76.79 each to cover tax withholding obligations.

Summary

• Daniel J. Lippis, the CVP, JAPAC at Edwards Lifesciences Corp. (EW), reported a transaction on July 7, 2025.
• The transaction involved the disposition of 333 shares of common stock.
• The shares were disposed of at a price of $76.79 per share.
• The purpose of the disposition (Transaction Code 'F') was to satisfy tax withholding obligations.
• Following this transaction, Daniel J. Lippis directly beneficially owns 26,115.9103 shares of Edwards Lifesciences common stock.
• The filing notes that it includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan, though the specific acquisition details are not itemized in this Form 4.

Sentiment

Score: 5

Explanation: The transaction is a routine disposition of shares to cover tax withholding obligations, which is a standard practice for equity compensation and does not indicate a change in management's sentiment towards the company's prospects.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Disposition of 333 common shares by Daniel J. Lippis, an officer of Edwards Lifesciences Corp., to the issuer to satisfy tax withholding obligations related to equity compensation.

Stakeholder Impact

• Minimal direct impact on shareholders as the transaction is a routine disposition for tax withholding purposes, not a discretionary sale that would signal a change in confidence.

Key Dates

Keywords

Edwards Lifesciences, EW, Daniel J. Lippis, Form 4, insider transaction, stock disposition, tax withholding, beneficial ownership, common stock